Xlife Sciences Ltd. ( (CH:XLS) ) has provided an announcement.
Xlife Sciences AG has announced a strategic collaboration between its portfolio company Firstgene Life Sciences and Hovione to develop a novel gene therapy for hepatocellular carcinoma (HCC), a common form of liver cancer. This partnership marks Xlife Sciences’ entry into the gene therapy market, leveraging Hovione’s advanced gene therapy platform to address the significant unmet medical need in HCC treatment. The collaboration underscores Xlife Sciences’ commitment to innovation and its capacity to advance impactful therapeutic solutions, while also enhancing Hovione’s reach in oncology.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a company involved in the life sciences industry, focusing on the commercialization and business development of innovative projects. The company is expanding its portfolio into gene therapy, aiming to create synergies with existing portfolio companies and demonstrating its ability to collaborate with established industry partners.
YTD Price Performance: -23.23%
Average Trading Volume: 4,358
Current Market Cap: CHF112M
See more data about XLS stock on TipRanks’ Stock Analysis page.